Insiders who bought US$420.8k worth of InspireMD, Inc. (NASDAQ:NSPR) stock in the last year have seen some of their losses recouped as the stock gained 14% last week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$161k.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

InspireMD Insider Transactions Over The Last Year

In the last twelve months, the biggest single sale by an insider was when the insider, Shane Gleason, sold US$190k worth of shares at a price of US$3.65 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$0.74. So it is hard to draw any strong conclusion from it. Shane Gleason was the only individual insider to sell over the last year.

Over the last year, we can see that insiders have bought 350.12k shares worth US$421k. But insiders sold 146.49k shares worth US$289k. Overall, InspireMD insiders were net buyers during the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

InspireMD is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insiders At InspireMD Have Sold Stock Recently

The last three months saw some InspireMD insider selling. The selling netted US$190k for insider Shane Gleason. But US$148k was spent on buying, too, . While it's not great to see insider selling, the net amount sold isn't enough for us to want to read anything into it.

Insider Ownership Of InspireMD

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It appears that InspireMD insiders own 16% of the company, worth about US$5.6m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At InspireMD Tell Us?

Our data shows a little insider buying, but no selling, in the last three months. That said, the purchases were not large. But insiders have shown more of an appetite for the stock, over the last year. Overall we don't see anything to make us think InspireMD insiders are doubting the company, and they do own shares. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that InspireMD has 2 warning signs (1 is concerning!) that deserve your attention before going any further with your analysis.

But note: InspireMD may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.